Bayer and Prof. Tal Dvir’s lab at Tel Aviv University have signed an agreement for research collaboration, in which Bayer will test new drugs on human 3D heart tissues printed at Prof. Dvir’s lab.
This technology, developed by Prof. Dvir, is currently under development by Matricelf. Matricelf licensed the technology that enabled printing the first functioning 3D human heart from cells and matrix derived from a human omentum biopsy. Prof. Dvir serves as Matricelf's Chief Scientist.
Prof. Tal Dvir's research has been supported by the Zimin Institute at TAU for Engineering Solutions Advancing Better Lives. In 2019, Prof Tal Dvir was selected as one of the 20 promising Israeli scientists for the new decade.
Matricelf believes that the collaboration between Bayer and Prof. Dvir’s lab will help the further development of spinal cord implants for paralyzed patients due to spinal cord injuries and greatly advance its plans for a clinical trial.
Dec 30, 2020
Zimin Institute at TAU Share:
TwitterFacebookLinkedIn
